Blog Posts
Oriol Mirallas
Oriol Mirallas/X

Oriol Mirallas: Early Data on SYNC-T Therapy for mCRPC Presented at ASCO 2025

Oriol Mirallas, Medical Oncology Specialist at Vall d’Hebron Institute of Oncology, shared a post on X:

“Drug Development
SYNC-T Therapy (image guided cryolisis + infusion of SV-102 (fixed dose PD1, CTLA4, CD40 an TLR9) for mCRPC
– Fever and hematuria
– 87% with 8 CR
– Only 15 patients
Dr. Tong.”

SYNC-T Therapy

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

ASCO

ASCO ASCO 2025 ASCO25 cancer OncoDaily Oncology Oriol Mirallas SYNC-T Therapy